VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI′

Molecular Immunology

Volumn 45, Issue 14, 2008, Pages 3847-3856

  Hmila, Issam ^a   Abdallah R, Ben Abderrazek Ben ^a   Saerens, Dirk ^b,c   Benlasfar, Zakaria ^a   Conrath, Katja ^b,c   Ayeb, Mohamed El ^a   Muyldermans, Serge ^b,c   Bouhaouala Zahar, Balkiss ^a,d  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

Dromedary; Nanobody; Phage display; Recombinant antibody; Scorpion venom; Serotherapy; Toxin

Indexed keywords

ANTIBODY; SCORPION VENOM; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VHH ANTIBODY;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PURIFICATION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; NONHUMAN; PRIORITY JOURNAL;

ANDROCTONUS AUSTRALIS HECTOR; CAMELUS DROMEDARIUS; SCORPIONES;

ANIMALS; ANTIBODIES; CAMELS; HUMANS; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SCORPION VENOMS; SCORPIONS;

EID: 48049096810     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.04.011     Document Type: Article

References (51)

1. Abroug F., Elatrous S., Nouira S., Haguiga H., Touzi N., and Bouchoucha S. Serotherapy in scorpion envenomation: a randomised controlled trial. Lancet 354 (1999) 906-909
2. Abroug F., Nouira S., Elatrous S., Besbes L., Boukef R., Boussarsar M., Marghli S., Eurin J., Barthelemy C., El Ayeb M., Dellagi K., and Carayon A. A canine study of immunotherapy in scorpion envenomation. Intensive Care Med. 29 (2003) 2266-2276
3. Aubrey N., Devaux C., Sizaret P.Y., Rochat H., Goyffon M., and Billiald P. Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin. Cell Mol. Life Sci. 60 (2003) 617-628
4. Aubrey N., Muzard J., Christophe Peter J., Rochat H., Goyffon M., Devaux C., and Billiald P. Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments. Toxicon 43 (2004) 233-241
5. Bahraoui E., Pichon J., Muller J.M., Darbon H., Elayeb M., Granier C., Marvaldi J., and Rochat H. Monoclonal antibodies to scorpion toxins. Characterization and molecular mechanisms of neutralization. J. Immunol. 141 (1988) 214-220
6. Baral T.N., Magez S., Stijlemans B., Conrath K., Vanhollebeke B., Pays E., Muyldermans S., and De Baetselier P. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat. Med. 12 (2006) 580-584
7. Bouhaouala-Zahar B., Ducancel F., Zenouaki I., Ben Khalifa R., Borchani L., Pelhate M., Boulain J.C., El Ayeb M., Menez A., and Karoui H. A recombinant insect-specific alpha-toxin of Buthus occitanus tunetanus scorpion confers protection against homologous mammal toxins. Eur. J. Biochem. 238 (1996) 653-660
8. Clot-Faybesse O., Juin M., Rochat H., and Devaux C. Monoclonal antibodies against the Androctonus australis hector scorpion neurotoxin I: characterisation and use for venom neutralisation. FEBS Lett. 458 (1999) 313-318
9. Conrath K.E., Lauwereys M., Wyns L., and Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. 276 (2001) 7346-7350
10. Conrath K.E., Lauwereys M., Galleni M., Matagne A., Frére J.M., Kinne J., Wyns L., and Muyldermans S. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 45 (2001) 2807-2812
11. Cortez-Retamozo V., Backmann N., Senter P.D., Wernery U., De Baetselier P., Muyldermans S., and Revets H. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 64 (2004) 2853-2857
12. Cortez-Retamozo V., Lauwereys M., Hassanzadeh Gh.G., Gobert M., Conrath K., Muyldermans S., De Baetselier P., and Revets H. Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer. 98 (2002) 456-462
13. De Genst E., Silence K., Decanniere K., Conrath K., Loris R., Kinne J., Muyldermans S., and Wyns L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 4586-45891
14. Delabre M.L., Pasero P., Marilley M., and Bougis P.E. Promoter structure and intron-exon organization of a scorpion alpha-toxin gene. Biochemistry 34 (1995) 6729-6736
15. Devaux C., Moreau E., Goyffon M., Rochat H., and Billiald P. Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector. Eur. J. Biochem. 268 (2001) 694-702
16. Dumoulin M., Conrath K., Van Meirhaeghe A., Meersman F., Heremans K., Frenken L.G.J., Muyldermans S., Wyns L., and Matagne A. Protein Sci. 11 (2002) 500-515
17. El Ayeb M., and Rochat H. Polymorphism and quantitative variations of toxins in the venom of the scorpion Androctonus australis hector. Toxicon 23 (1985) 755-760
18. El Ayeb M., Bahraoui E.M., Granier C., and Rochat H. Use of antibodies specific to defined regions of scorpion alpha-toxin to study its interaction with its receptor site on the sodium channel. Biochemistry 25 (1986) 6671-6678
19. Ghahroudi M.A., Desmyter A., Wyns L., Hamers R., and Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414 (1997) 521-526
20. Gueron M., and Ilia R. Is antivenom the most successful therapy in scorpion victims?. Toxicon 37 (1999) 1655-1657
21. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., and Hamers R. Naturally occurring antibodies devoid of light chains. Nature 363 (1993) 446-448
22. Hammoudi-Triki D., Lefort J., Rougeot C., Robbe-Vincent A., Bon C., Laraba-Djebari F., and Choumet V. Toxicokinetic and toxicodynamic analyses of Androctonus australis hector venom in rats: optimization of antivenom therapy. Toxicol. Appl. Pharmacol. 218 (2007) 205-214
23. Harmsen M.M., van Solt C.B., van Zijderveld-van Bemmel A.M., Niewold T.A., and van Zijderveld F.G. Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl. Microbiol. Biotechnol. 72 (2006) 544-555
24. Harmsen M.M., and De Haard H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77 (2007) 13-22
25. Hoogenboom H.R., Griffiths A.D., Johnson K.S., Chiswell D.J., Hudson P., and Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19 (1991) 4133-4137
26. Ismail M. The treatment of the scorpion envenoming syndrome: the Saudi experience with serotherapy. Toxicon 32 (1994) 1019-1026
27. Ismail M., and Abd-Elsalam M.A. Pharmacokinetics of 125I-labelled IgG, F(ab′)2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use. Toxicon 36 (1998) 1523-1528
28. Juárez-González V.R., Riaño-Umbarila L., Quintero-Hernández V., Olamendi-Portugal T., Ortiz-León M., Ortíz E., Possani L.D., and Becerril B. Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2. J. Mol. Biol. 346 (2005) 1287-1297
29. +-channel toxins protects against experimental scorpion envenoming. Cell Mol. Life Sci. 64 (2007) 206-218
30. Krifi M.N., Savin S., Debray M., Cassian B., El Ayeb M., and Choumet V. Pharmacokinetic studies of scorpion venom before and after antivenom immunotherapy. Toxicon 45 (2005) 187-198
31. Krifi M.N., Kharrat H., Zghal K., Abdouli M., Abroug F., Bouchoucha S., Dellagi K., and El Ayeb M. Development of an ELISA for the detection of scorpion venoms in sera of humans envenomed by Androctonus australis garzonii (Aag) and Buthus occitanus tunetanus (Bot): correlation with clinical severity of envenoming in Tunisia. Toxicon 36 (1998) 887-900
32. Krifi M.N., Miled K., Abderrazak M., and El Ayeb M. Effects of antivenom on Buthus occitanus tunetanus (Bot) scorpion venom pharmacokinetics: towards an optimization of antivenom immunotherapy in a rabbit model. Toxicon 39 (2001) 1317-1326
33. Lefranc M.P., Pommie C., Ruiz M., Giudicelli V., Foulquier E., Truong L., Thouvenin-Contet V., and Lefranc G. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev. Comp. Immunol. 27 (2003) 55-77
34. Meddeb-Mouelhi F., Bouhaouala-Zahar B., Benlasfar Z., Hammadi M., Mejri T., Moslah M., Karoui H., Khorchani T., and El Ayeb M. Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. Toxicon 42 (2003) 785-791
35. Miranda F., Kopeyan C., Rochat C., Rochat H., and Lissitzky S. Purification of animal neurotoxins. Isolation and characterization of eleven neurotoxins from the venoms of the scorpions Androctonus australis hector, Buthus occitanus tunetanus and Leiurus quinquestriatus quinquestriatus. Eur. J. Biochem. 16 (1970) 279-291
36. Mousli M., Devaux C., Rochat H., Goyffon M., and Billiald P. A recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector. FEBS Lett. 442 (1999) 183-188
37. Muyldermans S., Atarhouch T., Saldanha J., Barbosat J.A., and Hamers. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 7 (1994) 1129-1135
38. Muyldermans S., Cambillau C., and Wyns L. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem. Sci. 26 (2001) 230-235
39. Nguyen V.K., Desmyter A., and Muyldermans S. Functional heavy-chain antibodies in Camelidae. Adv. Immunol. 79 (2001) 261-296
40. Nguyen V.K., Zou X., Lauwereys M., Brys L., Brüggemann M., and Muyldermans S. Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells. Immunology 109 (2003) 93-101
41. Pace C.M., and Scholtz J.M. In: Creighton T.E. (Ed). Measuring The Conformational Stability of a Protein in Protein Structure: A Practical Approach (1997), Oxford University Press, New York 299-321
42. Reed L., and Muench H. A simple method of estimating fifty percent in eucariotic end point. Am. J. Hyg. 27 (1938) 493-497
43. Rezende N.A., Amaral C.F., and Freire-Maia L. Immunotherapy for scorpion envenoming in Brazil. Toxicon 36 (1998) 1507-1513
44. Rochat H., Rochat C., Miranda F., Lissitzky S., and Edman P. The amino acid sequence of neurotoxin I of Androctonus australis hector. Eur. J. Biochem. 17 (1970) 262-266
45. Saerens D., Kinne J., Bosmans E., Wernery U., Muyldermans S., and Conrath K. Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J. Biol. Chem. 279 (2004) 51965-51972
46. Sambrook J., and Russell D.W. Molecular Cloning: A Laboratory Manual. third ed. (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
47. Skerra A., and Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240 (1988) 1038-1041
48. Thomassen Y.E., Meijer W., Sierksra L., and Verrips C.T. Enzyme Microb. Technol. 30 (2002) 273-278
49. Van de Laar T., Visser C., Holster M., López C.G., Kreuning D., Sierkstra L., Lindner N., and Verrips T. Increased heterologous protein production by Saccharomyces cerevisiae growing on ethanol as sole carbon source. Biotechnol. Bioeng. 96 (2007) 483-494
50. Vu K.B., Ghahroudi M.A., Wyns L., and Muyldermans S. Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol. Immunol. 34 (1997) 1121-1131
51. Willuda J., Honegger A., Waibel R., Schubiger P.A., Stahel R., Zangemeister-Wittke U., and Plückthun A. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. 59 (1999) 5758-5767